137 related articles for article (PubMed ID: 20073617)
1. Basal-like breast carcinoma: a phenotypically distinct entity.
Haupt B; Ro JY; Schwartz MR
Arch Pathol Lab Med; 2010 Jan; 134(1):130-3. PubMed ID: 20073617
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
3. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
4. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
5. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.
Moestue SA; Borgan E; Huuse EM; Lindholm EM; Sitter B; Børresen-Dale AL; Engebraaten O; Maelandsmo GM; Gribbestad IS
BMC Cancer; 2010 Aug; 10():433. PubMed ID: 20716336
[TBL] [Abstract][Full Text] [Related]
6. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of morphologic features to identify "basal-like phenotype" on core needle biopsies of breast.
Chivukula M; Striebel JM; Erşahin C; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):411-6. PubMed ID: 18542031
[TBL] [Abstract][Full Text] [Related]
8. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
9. [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas].
Vincent-Salomon A; Macgrogan G; Charaffe-Jauffret E; Jacquemier J; Arnould L
Bull Cancer; 2010 Mar; 97(3):357-63. PubMed ID: 20197250
[TBL] [Abstract][Full Text] [Related]
10. Low methylation levels of the SFRP1 gene are associated with the basal-like subtype of breast cancer.
Jeong YJ; Jeong HY; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 May; 29(5):1946-54. PubMed ID: 23467623
[TBL] [Abstract][Full Text] [Related]
11. Is 'basal-like' carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes.
Moinfar F
Pathobiology; 2008; 75(2):119-31. PubMed ID: 18544967
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Nielsen TO; Hsu FD; Jensen K; Cheang M; Karaca G; Hu Z; Hernandez-Boussard T; Livasy C; Cowan D; Dressler L; Akslen LA; Ragaz J; Gown AM; Gilks CB; van de Rijn M; Perou CM
Clin Cancer Res; 2004 Aug; 10(16):5367-74. PubMed ID: 15328174
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
15. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
[TBL] [Abstract][Full Text] [Related]
16. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
18. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
[TBL] [Abstract][Full Text] [Related]
19. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic study of centrally necrotizing carcinoma of breast].
Yu L; Yang WT; Cai X; Lu HF; Fan YZ; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):657-62. PubMed ID: 20078968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]